Monday, October 19, 2009

Future of Serada - Discussion With Depomed CEO Carl Pelzel

What does the future hold in store for Depomed’s (DEPO-$3.60) investigational non-hormonal therapeutic option for the treatment of menopausal hot flashes, Serada? In an exclusive interview, chief executive Carl Pelzel shared his thoughts with me on the higher-than-expected efficacy seen with patients given placebo and possible outcomes from a likely meeting with the FDA in December. Continue Reading at BNET PHARMA Industries….

No comments: